Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
NCT01520805
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Interventions
DRUG:
CPI-613
Sponsor
Cornerstone Pharmaceuticals